## **Core Concept**
The question assesses knowledge of the hepatotoxic potential of various anti-tuberculosis (TB) drugs. Anti-TB drugs can cause liver injury, ranging from mild elevations in liver enzymes to severe hepatitis. The risk of hepatotoxicity varies among different drugs used in the treatment of TB.

## **Why the Correct Answer is Right**
Ethambutol (**Option D**) is considered the least hepatotoxic among the first-line anti-TB drugs. The primary concern with ethambutol is optic neuritis leading to visual disturbances, not hepatotoxicity. In contrast, isoniazid, rifampicin, and pyrazinamide are well-known for their potential to cause liver damage. Isoniazid and rifampicin can cause mild elevations in liver enzymes, while pyrazinamide has a higher risk of severe hepatotoxicity.

## **Why Each Wrong Option is Incorrect**
- **Option A (Isoniazid):** Isoniazid is known to cause hepatotoxicity, particularly in older adults and those with pre-existing liver disease. It can lead to severe liver injury.
- **Option B (Rifampicin):** Rifampicin also carries a risk of hepatotoxicity, and when used in combination with isoniazid, the risk of liver injury may be increased.
- **Option C (Pyrazinamide):** Pyrazinamide has a higher risk of hepatotoxicity compared to ethambutol. It is often implicated in cases of severe anti-TB drug-induced liver injury.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that while monitoring for hepatotoxicity is crucial for all anti-TB drugs, ethambutol stands out as having a significantly lower risk of causing liver injury compared to the other first-line agents. Clinicians often consider the risk of hepatotoxicity when selecting anti-TB drugs, especially in patients with pre-existing liver conditions.

## **Correct Answer:** D. Ethambutol.